Greenwich LifeSciences (GLSI) Projected to Post Quarterly Earnings on Tuesday

Greenwich LifeSciences (NASDAQ:GLSI) is expected to release its results after the market closes on Tuesday, March 31st. Analysts expect Greenwich LifeSciences to post earnings of ($0.33) per share for the quarter.

Greenwich LifeSciences Price Performance

Shares of NASDAQ:GLSI opened at $25.34 on Friday. Greenwich LifeSciences has a 1 year low of $7.78 and a 1 year high of $34.10. The company has a market cap of $350.96 million, a P/E ratio of -17.36 and a beta of 1.50. The stock’s fifty day moving average price is $26.57 and its 200-day moving average price is $17.24.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the company. HC Wainwright boosted their target price on Greenwich LifeSciences from $39.00 to $50.00 and gave the stock a “buy” rating in a research report on Tuesday, December 30th. Wall Street Zen upgraded shares of Greenwich LifeSciences from a “sell” rating to a “hold” rating in a research note on Saturday, December 27th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Greenwich LifeSciences in a report on Monday, December 29th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Greenwich LifeSciences presently has an average rating of “Hold” and an average target price of $47.50.

Insider Activity

In other news, CEO Snehal Patel purchased 4,300 shares of the company’s stock in a transaction dated Wednesday, December 31st. The shares were purchased at an average cost of $21.36 per share, for a total transaction of $91,848.00. Following the purchase, the chief executive officer directly owned 5,599,402 shares in the company, valued at approximately $119,603,226.72. This represents a 0.08% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In the last quarter, insiders acquired 11,900 shares of company stock valued at $288,425. Company insiders own 51.47% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of GLSI. XTX Topco Ltd purchased a new position in Greenwich LifeSciences in the fourth quarter worth about $217,000. Man Group plc purchased a new stake in shares of Greenwich LifeSciences during the 4th quarter valued at about $590,000. Barclays PLC lifted its stake in shares of Greenwich LifeSciences by 11.8% in the 4th quarter. Barclays PLC now owns 9,744 shares of the company’s stock worth $205,000 after purchasing an additional 1,030 shares during the period. State Street Corp lifted its stake in shares of Greenwich LifeSciences by 19.3% in the 4th quarter. State Street Corp now owns 97,777 shares of the company’s stock worth $2,054,000 after purchasing an additional 15,831 shares during the period. Finally, Wells Fargo & Company MN boosted its holdings in shares of Greenwich LifeSciences by 109.6% in the fourth quarter. Wells Fargo & Company MN now owns 7,845 shares of the company’s stock worth $165,000 after buying an additional 4,102 shares during the last quarter. Institutional investors own 4.16% of the company’s stock.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc (NASDAQ: GLSI) is a clinical-stage biotechnology company focused on the development of novel immune modulators for the treatment of cancer and autoimmune diseases. The company’s product pipeline includes candidates engineered to activate or regulate key components of the innate and adaptive immune systems, with programs advancing through preclinical and early-stage clinical studies.

Headquartered in Greenwich, Connecticut, Greenwich LifeSciences conducts its research and development activities primarily in the United States.